ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Hodgkin Lymphoma in Philadelphia, PA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Cancer

Non-Hodgkin Lymphoma trials near Philadelphia, PA, USA:

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy

Phase 3

Novartis
Novartis

Philadelphia, Pennsylvania, United States and 66 other locations

The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed B-Cell Non-Hodgkin Lymphoma
Drug: Loncastuximab Tesirine
Drug: Polatuzumab Vedotin

Phase 1

ADC Therapeutics

Philadelphia, Pennsylvania, United States and 34 other locations

and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma...

Enrolling
Hodgkin Disease
Lymphoma, Non-Hodgkin
Drug: Relatlimab
Drug: Nivolumab

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Wilmington, Delaware, United States and 75 other locations

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
B Cell Lymphoma
Genetic: CB-010
Drug: Cyclophosphamide

Phase 1

Caribou Biosciences

Philadelphia, Pennsylvania, United States and 34 other locations

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...

Enrolling
Lymphoma, Non-Hodgkin
Drug: Fludarabine
Drug: JCAR017

Phase 2

Celgene
Celgene

Philadelphia, Pennsylvania, United States and 56 other locations

The purpose of this study is to evaluate the safety and preliminary efficacy of ATA3219 in participants with relapsed/refractory (R/R) B-cell non...

Enrolling
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Drug: ATA3219

Phase 1

Atara Biotherapeutics

Philadelphia, Pennsylvania, United States and 4 other locations

This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin L....

Enrolling
Mature B-cell Non-Hodgkin Lymphoma
Advanced Solid Tumor
Drug: ATG-101

Phase 1

Antengene
Antengene

Philadelphia, Pennsylvania, United States of America and 7 other locations

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purp-...

Enrolling
Non-Hodgkin Lymphoma
Drug: Pirtobrutinib
Drug: Ibrutinib

Phase 2

Genmab
Genmab

Philadelphia, Pennsylvania, United States and 74 other locations

This is an open-label phase I study to determine the safety and recommended phase 2 dose (RP2D) of Senza5 CART5 cells in patients with relapsed or re...

Enrolling
T Cell Non-Hodgkin Lymphoma
Drug: Senza5 CART5

Phase 1

Vittoria Biotherapeutics

Philadelphia, Pennsylvania, United States

clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two...

Enrolling
Non Hodgkin Lymphoma
Drug: Interleukin-2
Drug: Rituximab

Phase 1, Phase 2

Artiva Biotherapeutics

Philadelphia, Pennsylvania, United States of America and 20 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems